ASCO 2023: RemeGen Exhibits Promising Results of Disitamab V

YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on...

Related Keywords

China , United States , Yantai , Shandong , Chicago , Illinois , Prag , Praha , Hlavníesto , Czech Republic , Peking , Beijing , American , Fang Jianmin , Guo Jun , Remegen Co , University Cancer Hospital , American Society Of Clinical Oncology , Prnewswire Remegen Co Ltd , American Society , Clinical Oncology , Annual Meeting , Objective Response Rate , Complete Response , Disease Control Rate , Progression Free Survival , Overall Survival , Professor Guo Jun , Peking University Cancer Hospital , Chief Scientific Officer , Titles Released ,